Ross Maltz
Biographic Data
| ID | 8254067 |
|---|---|
| NAME | Ross Maltz |
| GIVEN NAMES | Ross |
| FAMILY NAME | Maltz |
| SIGNATURE | MALTZ R |
| AFFILIATIONS | Nationwide Children's Hospital |
| ORCID | 0000-0001-7850-7555 |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 2 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2021 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
Infliximab Biosimilar Utilization in a Large Pediatric Learning Health System
Background/Objectives : Infliximab biosimilars entered the United States (US) market in November 2016. Uptake of infliximab biosimilars has been slow in adult studies. We aimed to assess variation in the initiation of infliximab biosimilars in a large pediatric cohort. Methods : We performed a retrospective cohort study using data from 2016 to 2023 prospectively collected by the ImproveCareNow (ICN) Network, a multicenter pediatric inflammatory b…
Applying Telemedicine to Multidisciplinary Pediatric Inflammatory Bowel Disease Care
Multidisciplinary care is essential to the delivery of comprehensive, whole-person care for children and adolescents with inflammatory bowel disease (IBD). Team members may include medical, psychosocial, and ancillary providers as well as patient and family advocates. There is significant variability in how this care is delivered from center to center, though prior to the COVID-19 pandemic, most care occurred during in-person visits. At the onset…
No prominent works on this page.
Applying Telemedicine to Multidisciplinary Pediatric Inflammatory Bowel Disease Care
Multidisciplinary care is essential to the delivery of comprehensive, whole-person care for children and adolescents with inflammatory bowel disease (IBD). Team members may include medical, psychosocial, and ancillary providers as well as patient and family advocates. There is significant variability in how this care is delivered from center to center, though prior to the COVID-19 pandemic, most care occurred during in-person visits. At the onset…
Infliximab Biosimilar Utilization in a Large Pediatric Learning Health System
Background/Objectives : Infliximab biosimilars entered the United States (US) market in November 2016. Uptake of infliximab biosimilars has been slow in adult studies. We aimed to assess variation in the initiation of infliximab biosimilars in a large pediatric cohort. Methods : We performed a retrospective cohort study using data from 2016 to 2023 prospectively collected by the ImproveCareNow (ICN) Network, a multicenter pediatric inflammatory b…
Disease (2 works) · Inflammatory Bowel Disease (2 works) · Medicine (2 works) · Adolescent and Pediatric Healthcare (1 work) · Biosimilar (1 work) · Biosimilars and Bioanalytical Methods (1 work) · Cohort (1 work) · Context (archaeology (1 work) · Coronavirus disease 2019 (COVID-19 (1 work) · COVID-19 and healthcare impacts (1 work)